NCT06532279 2026-02-02
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
Phase 2 Recruiting
NRG Oncology
National Institutes of Health Clinical Center (CC)
Sir Mortimer B. Davis - Jewish General Hospital
M.D. Anderson Cancer Center
Banaras Hindu University
Mayo Clinic